<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701229</url>
  </required_header>
  <id_info>
    <org_study_id>SMD-RMB22 (29BRC20.0029)</org_study_id>
    <nct_id>NCT04701229</nct_id>
  </id_info>
  <brief_title>Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes</brief_title>
  <acronym>SMD-RMB22</acronym>
  <official_title>Impact of the Double Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes Isolated or Not Compared to the Single Haploinsufficiency of RBM22 and Normal Karyotype Myelodysplastic Syndromes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myelodysplastic syndromes (MDS) are malignant hematopathies of the elderly characterized by&#xD;
      persistent cytopenias and the presence of deregulated clonal hematopoiesis. The risk of&#xD;
      progression to acute myeloid leukemia (AML) is variable. Acquired cytogenetic abnormalities&#xD;
      are found in less than 50% of de novo cases and up to 80% in secondary MDS. The deletion of&#xD;
      the long arm of chromosome 5 (written del(5q)) is the most common abnormality in MDS (15%).&#xD;
      Del(5q) MDS has a good prognosis, with a median survival of 6 years and a 15% risk of&#xD;
      progression to AML. However, their life expectancy is shorter than the general population,&#xD;
      and the quality of life of patients is diminished. These treatments are not that effective&#xD;
      over a long period of time or not well tolerated, and the majority of patients die from&#xD;
      causes related to their MDS, such as infections (38%), progression to AML (15%), or bleeding&#xD;
      (13%). Two genes, RBM22 and SLU7, coding for proteins of the same complex involved in&#xD;
      splicing pre-messenger RNA are carried on the long arm of chromosome 5. We investigate the&#xD;
      pronostic impact and the predictive value of the double haploinsufficiency of the RBM22 and&#xD;
      SLU7 genes in del(5q) myelodysplastic syndromes isolated or not compared to the single&#xD;
      haploinsufficiency of RBM22 and normal karyotype myelodysplastic syndromes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prognostic impact on anemia</measure>
    <time_frame>retrospective study on data collected; 2 years</time_frame>
    <description>To evaluate the prognostic impact of the dual loss of an RBM22 and a SLU7 allele compared to the loss of an RBM22 allele alone on anemia, as measured by the hemoglobin level in the blood, between diagnosis and one year in patients with del5q myelodysplastic syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prognostic impact on blood count</measure>
    <time_frame>retrospective study on data collected; 2 years</time_frame>
    <description>To evaluate the prognostic impact of the double loss of an RBM22 allele and a SLU7 allele compared to the loss of an RBM22 allele alone on the other criteria of the blood count including leukocytes, platelets, monocytes, circulating blasts, VGM, myelemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic impact on progression to leukemia</measure>
    <time_frame>retrospective study on data collected; 2 years</time_frame>
    <description>To evaluate the prognostic impact of the double loss of an RBM22 and a SLU7 allele compared to the loss of an RBM22 allele alone on the progression to acute myeloid leukemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact on gene expression and splicing profile</measure>
    <time_frame>retrospective study on RNA collected; 2 years</time_frame>
    <description>To evaluate the impact of the double loss of an RBM22 allele and a SLU7 allele compared to the loss of an RBM22 allele alone on gene expression profiles, including splicing variants.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic Syndrome With Isolated Del(5Q)</condition>
  <condition>Myelodysplastic Syndrome With Del(5Q)</condition>
  <arm_group>
    <arm_group_label>normal karyotype</arm_group_label>
    <description>control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>del5q-RBM22neg-SLU7neg</arm_group_label>
    <description>this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22, a loss of SLU7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>del5q-RBM22neg-SLU7pos</arm_group_label>
    <description>this group is characterized by its karyotype. It presents a 5q deletion, a loss of RBM22 but no loss of SLU7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>del5q-RBM22pos-SLU7neg</arm_group_label>
    <description>this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22, but a loss in SLU7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>del5q-RBM22pos-SLU7pos</arm_group_label>
    <description>this group is characterized by its karyotype. It presents a 5q deletion, and no loss of RBM22 nor SLU7</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>somatic cytogenetic and genetic characterization</intervention_name>
    <description>investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.</description>
    <arm_group_label>del5q-RBM22neg-SLU7neg</arm_group_label>
    <arm_group_label>del5q-RBM22neg-SLU7pos</arm_group_label>
    <arm_group_label>del5q-RBM22pos-SLU7neg</arm_group_label>
    <arm_group_label>del5q-RBM22pos-SLU7pos</arm_group_label>
    <arm_group_label>normal karyotype</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cytogenetic pellets; bone marrow patients cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with myelodysplastic syndromes and presenting a deletion of chromosome 5&#xD;
        in their bone marrow cells&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with del5q MDS isolated or not&#xD;
&#xD;
          -  The clinical and biological data are known at the time of diagnosis.&#xD;
&#xD;
          -  The clinical and biological data are known 1 year after the diagnosis&#xD;
&#xD;
          -  Consent for the collection of samples for research purposes&#xD;
&#xD;
          -  Non-opposition obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under judicial protection (guardianship, ...)&#xD;
&#xD;
          -  Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Bérengère TROADEC</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Bérengère TROADEC</last_name>
    <phone>(33)298223324</phone>
    <email>marie-berengere.troadec@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie DOUET-GUILBERT</last_name>
    <phone>(33)298223324</phone>
    <email>nathalie.douet-guilbert@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Bérengère TROADEC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Français de cytogénétique Hématologique</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Nguyen-Khac</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Français des Myélodysplasies</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Fontenay</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RBM22</keyword>
  <keyword>SLU7</keyword>
  <keyword>transformation to acute myeloid leukemia</keyword>
  <keyword>anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning three years and ending fifteen years following the publication</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

